<sup>125</sup>I Research Reagents



Research use only. Not for use in diagnostic procedures

## [<sup>125</sup>I] α-Bungarotoxin

**Product Number: NEX126H** 

## LOT SPECIFIC INFORMATION:

CALCULATED AS OF: 12-Aug-2024

LOT NUMBER: LW91340

SPECIFIC ACTIVITY: 81.4 TBq/mmol

2200 Ci/mmol 10 MBq/μg 271 μCi/μg Package Size Information

Package Size	
as of	
13-Sep-2024	
1.85 MBq	
50 μCi	
9.25 MBq	
250 μCi	

RADIOCHEMICAL PURITY: ≥ 95%

MOLECULAR WEIGHT: ~8,119

**PACKAGING:** [1251] α-Bungarotoxin is lyophilized from a solution containing 0.04M sodium phosphate, 1M glycine, 0.2M NaCl, 0.25% BSA, 500 KIU/ml Trasylol® at pH 7.2. It is shipped ambient.

**STABILITY AND STORAGE:** The lyophilized [ $^{125}$ l]  $\alpha$ -Bungarotoxin should be stored at 4°C or lower. Following reconstitution with distilled water to a concentration of approximately 250  $\mu$ Ci/ml on calibration date, aliquot and store at -20°C or lower. Under these conditions the product is stable and usable in receptor assays for at least four weeks after fresh lot date.

**SPECIFIC ACTIVITY:** The initial specific activity is 2200 Ci/mmol (81 TBq/mmol), 271  $\mu$ Ci/ $\mu$ g (10 MBq/ $\mu$ g). Preparative HPLC is used to separate unlabeled a-Bungarotoxin from [ $^{125}$ I] a-Bungarotoxin. Upon decay, the product undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular or peptide fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on  $^{125}$ I decay and decay catastrophe of  $^{125}$ I labeled compounds are available. $^{1-5}$ 

**PREPARATIVE PROCEDURE**  $\alpha$ -Bungarotoxin is radioiodinated with no carrier added <sup>125</sup>I using a lactoperoxidase procedure<sup>6</sup> and is purified by reversed phase HPLC. This procedure has been shown to iodinate  $\alpha$ -Bungarotoxin only on Tyr<sup>54</sup>.<sup>7</sup>

RADIOCHEMICAL PURITY: Initially less than 5% free lodide.

**ΑνΑΙΔΑΘΙΔΙ Ι.** [<sup>--</sup>]α-συηθαιοτοχίη is τουτίπεις available from stock and is prepared fresh and packaged for shipment on the second Monday of each month. Please inquire for larger package sizes.

**HAZARD WARNING**: This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion and inhalation. It is irritating to the eyes, skin and respiratory tract and is toxic.

**RADIATION UNSHIELDED:** 280mR/hr/mCi at vial surface. **REFERENCES:** 

- 1. Doyle, V.M., Buhler, F.R., Burgisser, E., Eur. J. Pharm. 99 353 (1984).
- 2. Schmidt, J., J. Biol. Chem. 259 1660 (1984).
- 3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., J. Biol. Chem. 257 1418 (1982).
- 4. Berridge, M.S., Jiang, V.W., Welch, M.J., Rad. Res. 82 467 (1980).
- 5. Charlton, D.E., Rad. Res. 107 163 (1986).
- 6. Marchalonis, J.J., Biochemical Journal 113 299 (1969)
- 7. Wang, G.K. and Schmidt, J. J. Biol. Chem. 255 11156-11162 (1980).

## IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations: Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	.977	.955	.933	.912	.891	.871	.851	.831	.812
20	.794	.776	.758	.741	.724	.707	.691	.675	.660	.645
40	.630	.616	.602	.588	.574	.561	.548	.536	.524	.512
60	.500	.489	.477	.467	.456	.445	.435	.425	.416	.406
80	.397	.388	.379	.370	.362	.354	.345	.338	.330	.322
100	.315	.308	.301	.294	.287	.281	.274	.268	.262	.256
120	.250	.244	.239	.233	.228	.223	.218	.213	.208	.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

